Abstract:Background: Short interfering RNA (siRNA), highly capable of knockdown of specific genes, has emerged as a promising molecular therapeutic tool in targeted cancer treatment. Nonetheless, only limited success has been achieved in the systematic administration of siRNA. Therefore, the lack of a robust and versatile siRNA delivery system is a critical issue in translating this therapeutic tool for cancer treatment. Recent development in DNA nanotechnology has made programmable DNA nanoparticles (DNPs) a potent drug delivery platform. Rationally designed DNPs have emerged as facile delivery vehicles since their physicochemical properties can be precisely controlled compared to other delivery systems. This study focuses on the development of tumor targeted novel DNP-based siRNA delivery system to knockdown Bcl2 gene, as a targeted cancer therapeutic. Methods: Structural DNA technology was applied to design a library of DNPs with different sizes and shapes. Flow cytometry, confocal imaging, and transmission electron microscopy (TEM) were utilized to study the cellular internalization of DNPs. The efficacy of Bcl2 knockdown by DNP-siBcl2 and the resulting influence on cell growth and progression were assessed in cancer cells (in vitro) and in mice bearing corresponding tumor xenografts (in vivo). Results: The correlation between DNPs design (size, shape, tumor-targeting) and internalization efficiency in different cancer cell lines remains elusive. We investigated the cellular uptake of different sizes and shapes of DNPs with or without aptamer (nucleolin targeting molecule) in multiple human cancer cell lines. The cellular uptake efficiency of DNPs was influenced by targeting ligand, size, shape, and cell line. We observed distinct stages of the internalization process of a gold nanoparticle (AuNP)-tagged DNP, using high-resolution TEM. This study provides detailed understanding of cellular uptake and intracellular trafficking of DNPs in cancer cells. Anti-cancer therapeutic potential of siBcl2 delivered by DNPs were studied in mice bearing DMS53 tumor xenografts. Significant tumor growth inhibition was observed in mice treated with DNPs-siBcl2 (5 mg/kg or 10 mg/kg, IV) relative to vehicle alone and naked siBcl2. No toxicity was observed by pathologic examination of lung, liver, kidney, heart, brain, or spleen. Conclusions: Our study offers new insights for future optimization of DNP-based drug delivery systems for cancer therapy. Our novel aptamer conjugated DNP formulations demonstrated substantial cellular internalization. Targeting Bcl2 and its downstream signaling intermediaries reduced cellular growth. We validated the strategy of silencing of Bcl2 using DNPs in order to inhibit cancer progression in vivo. We believe that the DNPs and methodologies developed in this project will be applicable to knockdown of Bcl2 and other gene targets and may be an excellent platform to apply in future anti-cancer therapy. Citation Format: Mohammad Aminur Rahman, Pengfei Wang, Dongsheng Wang, Sreenivas Nannapaneni, Selwyn J. Hurwitz, Zhuo G. Chen, Yonggang Ke, Dong M. Shin. Targeted Bcl2 siRNA delivery using DNA nanoparticles in cancer therapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 3701.

In Situ Formation of Fibronectin‐Enriched Protein Corona on Epigenetic Nanocarrier for Enhanced Synthetic Lethal Therapy

Bilayer nanocarrier with protein-acid conjugation for prolonged release and enhanced anticancer effects.

Polymeric Nanostructure Compiled with Multifunctional Components to Exert Tumor-Targeted Delivery of Antiangiogenic Gene for Tumor Growth Suppression

Nanodelivery of a Self-Assembling Prodrug with Exceptionally High Drug Loading Potentiates Chemotherapy Efficacy.

Efficient bionic nanozyme based on AuPt NPs@ZIF-90 used for cyclic catalysis multimodal tumor therapy

A nanoplatform based on allylthiopurine bio-MOF and glycosylated AIE PARP inhibitor for cancer synthetic lethal therapy

Tumor microenvironment-activated cancer cell membrane-liposome hybrid nanoparticle-mediated synergistic metabolic therapy and chemotherapy for non-small cell lung cancer

Nanoenabled IL-15 Superagonist via Conditionally Stabilized Protein-Protein Interactions Eradicates Solid Tumors by Precise Immunomodulation

Synthetic Lethality in non-BRCA Mutant PDAC with Codelivery JQ1 and Olaparib via a Plectin1 Targeting Peptide Nanoparticle

Dendritic Nanomedicine with Boronate Bonds for Augmented Chemo‐immunotherapy via Synergistic Modulation of Tumor Immune Microenvironment

Enhanced theranostic efficacy of epirubicin-loaded SPION@MSN through co-delivery of an anti-miR-21 expressing plasmid and ZIF-8 hybridization to target colon adenocarcinoma

Enhancement of tumor immunogenicity by the introduction of non- proteinogenic amino acid azetidine-2-carboxylic acid

High drug loading and pH-responsive nanomedicines driven by dynamic boronate covalent chemistry for potent cancer immunotherapy

Visualized and Cascade-Enhanced Gene Silencing by Smart DNAzyme-graphene Nanocomplex

Engineered (NH2)-MIL-125(Ti)/copolymer@MnFe2O4 nanocomposite for synergistic eradication of cancer cells via DOX/pCRISPR delivery

CX-5461-loaded Nucleolus-Targeting Nanoplatform for Cancer Therapy Through Induction of Pro-Death Autophagy.

Abstract 3701: Targeted Bcl2 Sirna Delivery Using DNA Nanoparticles in Cancer Therapy

Genetically Engineered Protein Corona‐based Cascade Nanozymes for Enhanced Tumor Therapy

A Biodegradable Amphiphilic and Cationic Triblock Copolymer for the Delivery of Sirna Targeting the Acid Ceramidase Gene for Cancer Therapy

DNAzyme‐Assisted Nano‐Herb Delivery System for Multiple Tumor Immune Activation

In situ low-immunogenic albumin-conjugating-corona guiding nanoparticles for tumor-targeting chemotherapy